US stocks rebounded on Tuesday, February 24, 2026, with major indexes clawing back part of Monday’s AI-driven selloff as software and AI beneficiaries led a broad relief rally ahead of closely watched Nvidia earnings scheduled for tomorrow, Wednesday.

Index performance

• The Dow Jones Industrial Average added roughly 0.8%, a gain of around 400 points, helped by a turnaround in tech and prior-day laggards such as IBM and Oracle.
• The S&P 500 rose about 0.8%, with technology and consumer discretionary shares pacing the advance.
• The Nasdaq Composite climbed close to 1% as large-cap chip and software names rebounded, outpacing the broader market after leading Monday’s declines.
• The Russell 200 small caps closed up 1.22% at 2,652.49.

Drivers: AI relief and software rebound

• A sharp “AI scare trade” on Monday—triggered by fears that rapid automation could push US unemployment above 10% by 2028—reversed as investors focused on AI as an incremental growth driver rather than an immediate existential threat.
• Software stocks outperformed after Anthropic’s event highlighted new enterprise-focused AI tools and integrations, easing worries that AI would fully displace traditional software business models.
• An AI-focused software ETF jumped more than 3%, and names tied to Anthropic partnerships, including Salesforce (CRM, $185.46, +4.10%), FactSet, and DocuSign, posted notable gains.

Notable corporate movers

• AMD surged after Meta agreed to buy a massive tranche of its GPUs in a deal reported to exceed 100 billion dollars over time, rekindling enthusiasm around AI infrastructure spending and lifting sentiment across the chip complex, including Nvidia (NVDA, $292.85, +.68%).
• Workday rebounded from 52‑week lows as investors looked to its upcoming earnings for clarity on how AI is shaping software demand and margins.
• Tesla rose roughly 2.39% despite reporting a 17% drop in European sales and ongoing legal and regulatory overhangs, underscoring continued dip-buying interest in high‑beta growth names.
• Spirit Airlines advanced after reaching a deal with creditors aimed at exiting bankruptcy by late spring or early summer, signaling progress on its restructuring path.
• ImmunityBio, Inc. (Nasdaq: IBRX, $11.55, +17.50%), a commercial-stage biotechnology company pioneering next-generation immunotherapies, today announced that its Founder, Executive Chairman, and Global Chief Scientific and Medical Officer, Dr. Patrick Soon-Shiong, will participate as a featured speaker at “Cancer 2035: A Roadmap for the Future,” a landmark summit co-hosted by the Milken Institute and the Richard Nixon Foundation in Washington, D.C. on February 23–24, 2026.

Policy, tariffs, and macro backdrop

• President Donald Trump’s new 10% global tariff regime formally took effect at midnight, keeping trade and supply-chain uncertainty front and center as investors await further detail in the upcoming State of the Union address.
• Federal Reserve Governor Lisa Cook warned that traditional monetary policy tools may struggle to manage AI-driven labor-market disruptions without sparking inflation, highlighting a more complex policy landscape in coming years.
• The US dollar firmed modestly against major peers, while bitcoin pared earlier losses to trade near the mid‑60,000s and gold futures slipped as risk appetite improved.
• The 2‑year and 10‑year Treasury yields both inched higher today, keeping the curve modestly inverted but a bit less so than in recent sessions.

Economic data and positioning ahead

• The Conference Board’s consumer confidence index ticked up by 2.2 points in February to about 91, as households reported a slightly better outlook even as views on current conditions softened.
• Today’s advance marked only a partial recovery from Monday’s broad selloff, but the synchronized rise in the Dow, S&P 500, and Nasdaq suggested investors are selectively re‑embracing the AI and software trade heading into Nvidia’s results midweek.

VP Watchlist Updates

Below is an update‑style snapshot on the VP Watchlist names for the week, focused on recent catalysts, positioning, and narrative rather than precise price moves.

Eupraxia Pharmaceuticals (EPRX, $8.09)

Eupraxia Pharmaceuticals Inc. (“Eupraxia” or the “Company”), a clinical-stage biotechnology company leveraging its proprietary Diffusphere™ technology designed to optimize local, controlled drug delivery for applications with significant unmet need, is pleased to announce the successful closing of its previously announced public offering (the “Offering”) of 7,607,145 common shares of the Company (the “Common Shares”), which includes the full exercise of the option to purchase additional shares granted to the underwriters, at a price to the public of US$7.00 per Common Share, and pre-funded warrants to purchase up to 1,428,571 Common Shares in lieu thereof (the “Pre-Funded Warrants”) at a price of US$6.99999 per Pre-Funded Warrant, which equals the public offering price per Common Share less the C$0.000001 per share exercise price of each Pre-Funded Warrant, for gross proceeds of approximately US$63.2 million, before deducting the underwriting commissions and estimated expenses incurred in connection with the Offering.“We are pleased to complete this financing, allowing us to significantly expand our pipeline, reach several additional development milestones with EP-104GI for eosinophilic esophagitis, and make meaningful progress towards commercial readiness,” said James Helliwell, CEO of Eupraxia. “We appreciate the support from both existing and new investors as we execute our mission and pursue the next phase of growth for Eupraxia.” Cantor and LifeSci Capital acted as joint book-running managers for the Offering. Bloom Burton and Craig-Hallum also acted as co-managers for the Offering. As previously stated, the Company intends to use the net proceeds from the Offering primarily for the continued advancement of EP-104GI for Eosinophilic Esophagitis, including the completion of ongoing preclinical studies, and Phase 2 clinical trials, preparations for a Phase 3 clinical trial including the related regulatory submissions, and manufacturing activities, and to undertake the necessary commercial/market development activities to prepare for the eventual product launch. The Company also intends to use a portion of the proceeds to accelerate and expand its plans to pursue clinical studies with EP-104GI in multiple additional gastrointestinal indications, including in esophageal strictures and fibrostenotic Crohn’s disease. A portion of the proceeds will be allocated to research and development of additional pipeline candidates, business development initiatives, and general corporate purposes, which may include but are not limited to employee salaries, working capital, leases for facilities, administrative expenses, and capital expenditures. The Company may also use a portion of the proceeds to expand its intellectual property portfolio and strengthen its corporate infrastructure to support future growth.

Modular Medical (MODD)

• Closed at $.4712. Has been trading as a diabetes‑tech name, with shares reacting to execution milestones around its Pivot tubeless patch pump platform.Earlier this month, the company began production of validation lots for its disposable cartridge and infusion set, keeping it on track for a planned commercial launch in the first quarter of 2026, contingent on FDA 510(k) clearance—an event path that positions upcoming regulatory decisions as key stock catalysts.
• Earlier this month, the company began production of validation lots for its disposable cartridge and infusion set, keeping it on track for a planned commercial launch in the first quarter of 2026, contingent on FDA 510(k) clearance—an event path that positions upcoming regulatory decisions as key stock catalysts.

FIGS, Inc. (FIGS, $10.96., +.46%)

FIGS, the direct‑to‑consumer healthcare apparel brand, operates at the intersection of e‑commerce and specialty retail, with a loyal professional customer base and a growing product portfolio. While macro headwinds and digital‑ad volatility have pressured some consumer names, FIGS’ brand equity in the medical community and ongoing product innovation offer levers for renewed growth as conditions normalize.

GeoVax Labs (GOVX, $1.60)

• GeoVax announced (Feb. 24) the formation of its Oncology Advisory Board with the appointment of three internationally recognized leaders in immuno-oncology, translational medicine, and clinical development. This Advisory Board will play a central role in guiding the scientific, translational, and clinical advancement of GeoVax’s oncology program, focused primarily on Gedeptin(R), the company’s gene-directed enzyme prodrug therapeutic (GDEPT). GeoVax plans to conduct a Phase 2 trial with Gedeptin in the neoadjuvant setting, pairing it with an immune checkpoint inhibitor (ICI) in locally advanced head and neck squamous cell carcinoma. In parallel, it will be evaluating combination Gedeptin + ICI strategies across additional solid tumor indications.
• GeoVax announced on Wednesday, Feb. 18 that it has entered into an exclusive worldwide license agreement with Emory University for intellectual property covering the use of Gedeptin(R) in combination with immune checkpoint inhibitors (ICIs).
• On February 17, GOVX issued a statement endorsing the urgent call to action articulated by Rosamund Lewis, MD (WHO Head, Poxviruses Programme) and colleagues in their recently published PLOS Medicine article, “The mpox epidemic is not over: Reducing disproportionate burden in Africa and persistent global risk require a sustained response.” (https://journals.plos.org/plosmedicine/article/file?id=10.1371/journal.pmed.1004893&type=printable)
• Shares can gap sharply on any trial or regulatory update, positive or negative.

DoubleVerify (DV, $9.15, +3.39%)

• DV traded in the context of that modest risk‑off tone closing at $9.59; no major company‑specific headline surfaced in the reviewed sources.
• DoubleVerify continues to benefit from secular tailwinds in digital ad verification and brand safety as advertisers prioritize measurable, fraud‑free impressions across social, CTV, and open web channels. In an environment where macro uncertainty still pressures marketing budgets, DV’s performance‑oriented value proposition and recurring‑revenue profile keep it well positioned within the ad‑tech stack.

The InterGroup Corporation (INTG, $30.36 +7.58%)

• InterGroup Corporation delivered (Feb. 17) a notably stronger quarter, highlighted by a 20% jump in total revenue to $17.3 million and a 27% surge in hotel revenue as renovated rooms returned to service and travel demand improved. The company swung from a prior-year net loss to $1.0 million in net income, with operating income more than doubling to $2.0 million, underscoring better cost control and improved operating efficiency. Management further enhanced liquidity and sharpened strategic focus by selling a non-core 12‑unit Los Angeles multifamily property, generating a meaningful gain and additional working capital while maintaining stable performance across its real estate portfolio.

Serina Therapeutics (SER, $1.67, +6.37%)

• Serina Therapeutics, a clinical-stage biotechnology company advancing drug candidates enabled by its proprietary POZ Platform™ drug optimization technology, announced (Feb. 19) that the first patient has been enrolled in the Company’s Phase 1b registrational trial evaluating. The Phase 1b registrational study is designed to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of SER-252 in patients with advanced Parkinson’s disease whose symptoms are inadequately controlled by current standard-of-care therapies. Serina remains on track to initiate dosing during the current quarter, consistent with previously disclosed guidance.

Volato Group, Inc. (SOAR, +2.71%) & M2i Global, Inc. (MTWO)

• Volato and M2i Global reaffirmed their goal of closing their business combination in the first quarter of 2026, citing steady advancement through SEC review and integration planning as they move toward a combined listing. The deal, originally announced in 2025, will effectively transition Volato from a pure‑play private aviation operator into a diversified platform spanning aviation technology and critical minerals, with M2i shareholders expected to own the majority of the combined entity. Operationally, the partnership is already visible: the two companies recently initiated their first shipment of titanium ore from Western Australia to the United States from Titanium X, underscoring how the critical‑minerals vertical could become a meaningful growth engine as domestic supply‑chain security rises in strategic importance.
• On Feb. 4, M2i Global,Inc.along with Volato Group, Inc. announced that Titanium X has initiated its first shipment of titanium ore from Western Australia to the U.S. under its collaboration agreement.

NVIDIA (NVDA, $192.85, +.68%)

• Nvidia stays at the center of the AI trade as hyperscale and enterprise demand for accelerated computing remains robust, even as some of its high‑end H‑series chips remain subject to legacy Section 232 tariff structures. The Supreme Court decision removes one layer of tariff uncertainty, and while new trade measures could emerge, the company’s strong pricing power and product cycle momentum continue to underpin the bull case.
• Nvidia is set to release its fiscal fourth-quarter (Q4) 2026 earnings on Wednesday, February 25, 2026, after the market closes. Analysts are projecting revenue of around $65.7 billion to $66.1 billion, which would represent approximately 67%-68% year-over-year growth.

McDonald’s (MCD, $333.05)

• Options data around the February 2026 expiries highlight active positioning near the 300–305 strike range, consistent with expectations for steady but not explosive upside from here.
• In the run-up to World Protein Day on 27th February, McDonald’s India (West & South), owned and operated by Westlife Foodworld, is celebrating Protein Week, reinforcing its leadership in nutrition-led innovation. Making protein more accessible, affordable and customizable, Indian consumers can use the McDonald’s app to explore these nutritious offerings and avail of protein burgers starting at just INR 69. Enhancing this convenience, consumers ordering via McDelivery can also enjoy free delivery on the Protein Plus meal range.

Nokia (NOK, $7.57)

• Nokia remains a value‑tilted telecom and network‑equipment play that is trading more with global cyclical and communications hardware sentiment than with high‑beta tech, and it did not appear as a major driver in today’s U.S.‑centric headlines.
• On Feb. 24, Nokia and AWS showcase industry-first agentic AI-powered network slicing with du and Orange
  • Industry-first intent-based 5G-Advanced slicing with agentic AI offers telecommunication providers with premium network slicing services that respond to real-world situations and enable autonomous intelligence.
  • This breakthrough innovation inferences and leverages open Internet data, including traffic, events, locations, maps and operator data for network slicing business.
  • du and Orange first to explore this innovative slicing solution that adapts automatically to support customer demand.

Opendoor (OPEN, $5.11, +6.90%)

• Opendoor Technologies, a leading e-commerce platform for residential real estate transactions, reported financial results for its fourth quarter and year ended December 31, 2025. They highlighted the following: October 2025 acquisition cohort tracking as best-performing October in Company history; acquisitions increased 46% quarter-over-quarter while inventory days in possession reduced 23%.
• Opendoor continues to navigate a challenging housing backdrop characterized by still‑elevated mortgage rates and tight existing‑home inventories, which weigh on transaction volumes even as affordability slowly improves. The company’s focus on disciplined acquisition spreads, inventory turns, and ancillary services remains central to the investment debate as markets handicap the pace and magnitude of any 2026 housing recovery.

The Sources

1. Yahoo Finance – “Dow, S&P 500, Nasdaq jump as software leads AI relief rally ahead of Nvidia earnings”[ca.finance.yahoo]​
   https://finance.yahoo.com/news/live/stock-market-today-dow-sp-500-nasdaq-jump-as-software-leads-ai-relief-rally-ahead-of-nvidia-earnings-210010666.html
2. Yahoo Finance – “Dow, S&P 500, Nasdaq climb as software stocks lead AI relief rally”[finance.yahoo]​
   https://finance.yahoo.com/news/live/stock-market-today-dow-sp-500-nasdaq-climb-as-software-stocks-lead-ai-relief-rally-143829839.html
3. Reuters – “Wall St bounces back on renewed tech vigor, easing AI concerns”[reuters]​
   https://www.reuters.com/business/us-stock-futures-steady-after-mondays-battering-tariffs-ai-concerns-dominate-2026-02-24/
4. Barron’s – “Stock Market Today: Dow, S&P 500, Nasdaq Rise”[barrons]​
   https://www.barrons.com/livecoverage/stock-market-news-today-022426
5. Wall Street Journal – “Stock Market Today: Dow Rises; AMD Rallies After Meta Deal”[wsj]​
   https://www.wsj.com/livecoverage/stock-market-today-dow-sp-500-nasdaq-02-24-2026
6. CNBC – “Stock market news for Feb. 24, 2026”[cnbc]​
   https://www.cnbc.com/2026/02/23/stock-market-today-live-updates.html
7. Investopedia – “Stock Market Today: Major Indexes Rebound After Sell-Off”[investopedia]​
   https://www.investopedia.com/stock-market-today-dow-jones-s-and-p-500-02242026-11912762
8. Reuters – “US software stocks climb as Anthropic announcement sparks relief rally”[reuters]​
   https://www.reuters.com/business/finance/us-software-stocks-climb-anthropic-announcement-sparks-relief-rally-2026-02-24/
9. The Street – “Stock Market Today, Feb. 24: Anthropic strikes again with new AI tools”[thestreet]​
   https://www.thestreet.com/latest-news/stock-market-today-feb-24-anthropic-strikes-again-with-new-ai-legal-tools
10. CNBC – “U.S. Treasury yields: Trump’s State of the Union speech”[cnbc]​
    https://www.cnbc.com/2026/02/24/us-treasury-yields-trumps-state-of-the-union-speech.html
11. Trading Economics – “US 2 Year Treasury Bond Note Yield”[tradingeconomics]​
    https://tradingeconomics.com/united-states/2-year-note-yield
12. YCharts – “2 Year Treasury Rate – Real-Time & Historical Yield Trends”[ycharts]​
    https://ycharts.com/indicators/2_year_treasury_rate
13. Trading Economics – “US 10 Year Treasury Note Yield”[tradingeconomics]​
    https://tradingeconomics.com/united-states/government-bond-yield
14. YCharts – “10 Year Treasury Rate – Real-Time & Historical Yield Trends”[ycharts]​
    https://ycharts.com/indicators/10_year_treasury_rate
15. Morningstar – “10-Year Treasury Yield Rises to 4.032% — Data Talk”[morningstar]​
    https://www.morningstar.com/news/dow-jones/202602249289/10-year-treasury-yield-rises-to-4032-data-talk
16. Federal Reserve FRED – “Market Yield on U.S. Treasury Securities at 2-Year Constant Maturity (DGS2)”[fred.stlouisfed]​
    https://fred.stlouisfed.org/series/DGS2
17. Federal Reserve FRED – “Market Yield on U.S. Treasury Securities at 10-Year Constant Maturity (DGS10)”[fred.stlouisfed]​
    https://fred.stlouisfed.org/series/DGS10
18. Federal Reserve FRED – “10-Year Treasury Constant Maturity Minus 2-Year Treasury (T10Y2Y)”[fred.stlouisfed]​
    https://fred.stlouisfed.org/series/T10Y2Y
19. GlobeNewswire – “The InterGroup Corporation Reports Improved Operating Results”[globenewswire]​
    https://www.globenewswire.com/news-release/2026/02/17/3239746/0/en/The-InterGroup-Corporation-Reports-Improved-Operating-Results.html
20. Yahoo Finance – “The InterGroup Corporation Reports Improved Operating Results; Completes Sale of a Non-Core Los Angeles Multifamily Property”[finance.yahoo]​
    https://finance.yahoo.com/news/intergroup-corporation-reports-improved-operating-210500839.html